Capital Fund Management S.A. Boosts Stock Holdings in Azenta, Inc. $AZTA

Capital Fund Management S.A. grew its position in Azenta, Inc. (NASDAQ:AZTA) by 35.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 151,506 shares of the company’s stock after acquiring an additional 39,245 shares during the quarter. Capital Fund Management S.A. owned about 0.33% of Azenta worth $4,663,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in AZTA. Mechanics Financial Corp raised its stake in Azenta by 77.6% in the 2nd quarter. Mechanics Financial Corp now owns 870 shares of the company’s stock valued at $27,000 after purchasing an additional 380 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Azenta by 41.6% during the second quarter. Farther Finance Advisors LLC now owns 1,371 shares of the company’s stock worth $42,000 after buying an additional 403 shares in the last quarter. CWM LLC grew its holdings in shares of Azenta by 113.5% during the second quarter. CWM LLC now owns 1,898 shares of the company’s stock worth $58,000 after buying an additional 1,009 shares in the last quarter. Allworth Financial LP raised its position in shares of Azenta by 29.1% in the second quarter. Allworth Financial LP now owns 2,050 shares of the company’s stock valued at $63,000 after buying an additional 462 shares during the last quarter. Finally, State of Wyoming lifted its stake in shares of Azenta by 77.1% in the first quarter. State of Wyoming now owns 2,343 shares of the company’s stock worth $81,000 after buying an additional 1,020 shares in the last quarter. 99.08% of the stock is owned by institutional investors and hedge funds.

Azenta Stock Performance

Shares of Azenta stock opened at $34.86 on Tuesday. The stock has a 50 day moving average of $31.35 and a 200 day moving average of $30.72. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -14.40 and a beta of 1.65. Azenta, Inc. has a fifty-two week low of $23.91 and a fifty-two week high of $55.63.

Azenta (NASDAQ:AZTA) last posted its earnings results on Friday, November 21st. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. The company had revenue of $159.19 million for the quarter, compared to the consensus estimate of $156.76 million. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.18 earnings per share. Analysts forecast that Azenta, Inc. will post 0.53 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AZTA. Jefferies Financial Group raised shares of Azenta from a “hold” rating to a “buy” rating and upped their price objective for the company from $30.00 to $38.00 in a research note on Thursday, October 30th. Raymond James Financial upped their price target on Azenta from $35.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, November 25th. Evercore ISI set a $33.00 price target on Azenta and gave the company an “in-line” rating in a report on Tuesday, August 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Azenta in a research note on Monday, November 24th. Finally, Zacks Research downgraded Azenta from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 25th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $38.60.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.